REFERENCES
- Gatenby R, Kessler H, Rosenblum J, et al. Oxygen distribu-tion in squamous cell carcinoma metastases and its relation-ship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988; 14: 831–8.
- Hirst DG. Anemia: a problem or an opportunity in radiother-apy? Int J Radiat Oncol Biol Phys 1986; 12: 2009–17.
- Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996; 6: 10–21.
- Henk JM. Does hyperbaric oxygen have a future in radiation therapy? Int J Radiat Oncol Biol Phys 1981; 7: 1125–8.
- Horsman MR, Chaplin DR, Overgaard J. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Res 1990; 50: 7430–6.
- Coleman CN. Radiation and chemotherapy sensitizers and protectors. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy: principles and practice. Philadelphia: Lippincott-Raven Publishers, 1996: 553–84.
- Dische SE. A review of hypoxic cell radiosensitization. Int J Radiat Oncol Biol Phys 1991; 20: 147–52.
- Brown JM. Hypoxic cell radiosensitizers: end of an era. Int J Radiat Oncol Biol Phys 1995; 32: 883–5.
- Raleigh JA, Dewhirst MW, Thrall DE. Measuring tumor hypoxia. Semin Radiat Oncol 1996; 6: 37–45.
- Stone HB, Brown JM, Phillips TL, Sutherland RM. Oxygen in human tumors: correlations between methods of measure-ment and response to therapy. Radiat Res 1993; 136: 422–34.
- Rigo P, Paulus P, Kaschten BJ, et al. Oncological applica-tions of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641–74.
- Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22: 199–212.
- Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36: 417–28.
- Yeh S-H, Liu R-S, Wu L-C, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996; 23: 1378–83.
- Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radiore-sistance with nuclear medicine assays. Radiother Oncol 1998; 46: 229–37.
- Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR. PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol 1996; 23: 717–35.
- Clavo AC, Brown RS, Wahl RL. 2-Fluoro-2-deoxy-D-glucose (FDG) uptake into human cancer cell lines is increased by hypoxia. J Nucl Med 1995; 36: 1625–32.
- Mellanen P, Minn H, Grenman R, Härkönen P. Expression of glucose transporters in head-and-neck tumors. Int J Cancer 1994; 56: 622–9.
- Weinhouse S. Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: G HA Clowes memo-rial lecture. Cancer Res 1972; 32: 2007–16.
- Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996; 23: 941–6.
- Varnes ME, Biaglow JE. Inhibition of glycolysis of mam-malian cells by misonidazole and other radiosensitizing drugs. Biochem Pharmacol 1982; 31: 2345–51.
- Varnes ME, Biaglow JE. Misonidazole-induced biochemical alterations of mammalian cells: effects on glycolysis. Int Radiat Oncol Biol Phys 1982; 8: 683–6.
- Pekkola-Heino K, Kulmala J, Grenman R. Sublethal damage repair in squamous cell carcinoma cell lines. Head Neck 1992; 14: 196–9.
- Passoneau JV. L-Lactate -fluorometric method. In: Bergmeyer HU, ed. Methods of enzymatic analysis. New York: Academic Press Inc, 1972: 1468–72.
- Toorongian SA, Mulholand GK, Jewett DM, Bachelor MA, Kilbourn MR. Routine production of 2-deoxy-2[F-18]fluoro-D-glucose by nucleophilic exchange on a quaternary 4-aminopyridinium resin. Int J Rad Appl Instrum [B] 1990; 17: 273–9.
- Overgaard J, Overgaard M, Nielsen OS, Kirstein Pedersen A, Timothy AR. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in C3H mammary carcinoma in vivo. Br J Cancer 1982; 46: 904–11.
- Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative methods for evaluating 24F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995; 196: 167–73.
- Overgaard J, Sand Hansen H, Overgaard M, et al. A random-ized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Radiother Oncol 1998; 46: 135–46.
- Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med 1997; 38: 1907–11.
- Kubota R, Yamada S, Kubota K. Intratumoral distribution of fluorine-18 fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microau-toradiography. J Nucl Med 1992; 33: 1972–80.
- Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary pospective evaluation. Radiology 1994; 191: 371–7.